Johnson & Johnson stock reports 6.6 percent revenue growth

Johnson & Johnson stock stood at USD 269.17 on the NYSE on September 23, 2026, while the healthcare group reported 6.6 percent year-over-year revenue growth in Q2 2026. Adjusted EPS reached USD 2.90, exceeding consensus by USD 0.06.

Q2 revenue clears estimates

Johnson & Johnson generated USD 25.31 billion in Q2 2026 revenue, compared with a consensus estimate of USD 25.06 billion, according to MarketBeat in a September 15, 2026 report.

The comparison matters because revenue growth and the earnings beat arrived together. Adjusted EPS of USD 2.90 also exceeded the USD 2.77 figure reported for the same quarter a year earlier, a year-over-year increase of 4.69 percent.

Cash flow sets the next test

At the Deutsche Bank Healthcare Summit on September 17, 2026, Johnson & Johnson said it expects USD 21 billion in 2026 free cash flow, as reported by Investing.com.

The company maintained fiscal 2026 adjusted EPS guidance of USD 11.60 to USD 11.75, while the reported Q2 margin was 21.48 percent. For investors, the key distinction is between operating momentum shown by the 6.6 percent revenue increase and the cash conversion needed to support the full-year outlook.

Stock remains below yearly high

Johnson & Johnson stock was USD 11.90 below its 52-week high of USD 281.07 on September 23, 2026, equal to a 4.23 percent gap. Its market capitalization stood at USD 648.67 billion on the same date, placing the quarterly earnings comparison against a large healthcare valuation.

The stock's reference price was USD 269.17 on the NYSE on September 23, 2026. The Q2 revenue beat, fiscal 2026 guidance range and USD 21 billion cash-flow outlook give the market three measurable operating points for assessing the shares.